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Key Points
• TL in LSCs is
significantly shortened
at diagnosis of CML
and correlates with
LSC burden.
• TL in nonleukemic




Telomere length (TL) inperipheralblood(PB)cellsofpatientswithchronicmyeloid leukemia (CML)
hasbeen shown to correlatewithdisease stage, prognostic scores, response to therapy, anddisease
progression. However, due to considerable genetic interindividual variability, TL varies sub-
stantially between individuals, limiting its use as a robust prognosticmarker in individual patients.
Here,we compared TL of BCR-ABL2, nonleukemic CD341CD382 hematopoietic stem cells (HSC) in
the bone marrow of CML patients at diagnosis to their individual BCR-ABL1 leukemic stem cell
(LSC) counterparts. We observed significantly accelerated telomere shortening in LSC compared
with nonleukemic HSC. Interestingly, the degree of LSC telomere shortening was found to
correlate significantly with the leukemic clone size. To validate the diagnostic value of
nonleukemic cells as internal controls and to rule out effects of tyrosine kinase inhibitor (TKI)
treatment on these nontarget cells, we prospectively assessed TL in 134 PB samples collected in
deepmolecular remission after TKI treatmentwithin theEURO-SKI study (NCT01596114).Here, no
significant telomere shortening was observed in granulocytes compared with an age-adjusted
control cohort. In conclusion, this study provides proof of principle for accelerated telomere
shortening in LSC as opposed to HSC in CML patients at diagnosis. The fact that the degree of
telomere shortening correlates with leukemic clone’s size supports the use of TL in leukemic cells
as a prognostic parameter pending prospective validation. TL in nonleukemicmyeloid cells seems
unaffected even by long-term TKI treatment arguing against a reduction of telomere-mediated
replicative reserve in normal hematopoiesis under TKI treatment.
Introduction
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell (HSC) disease caused by an
acquired reciprocal translocation between chromosomes 9 and 22 (the so-called Philadelphia
translocation, Ph) resulting in the BCR-ABL fusion gene. BCR-ABL, a constitutively active tyrosine
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kinase, promotes cell survival and proliferation through several
intracellular signal transduction pathways eventually leading to
malignant transformation.1 It is the primitive CML leukemic stem cell
(LSC) compartment that harbors the BCR-ABL translocation and
typically expands with disease progression.2
It is well established that the pathobiology of CML differs between
chronic phase (CP) and advanced stages, such as accelerated
phase (AP) and blast crisis (BC). Whereas CP is characterized
primarily by an increased cellular turnover and expansion of the
leukemic committed progenitor compartment, late stages of CML
typically acquire additional molecular aberrations, eventually leading
to a differentiation block resulting in increasing blast counts, and
secondarily, signs of hematopoietic insufficiency.3 At the stem cell
compartment level, LSCs typically represent a minority of HSC at
diagnosis. However, their contribution to the SC pool continuously
increases from early CP to late CP (reviewed by Eaves and Eaves2
and Alvarez et al4). Recently, it has been shown that the degree
of leukemic involvement in the HSC pool at diagnosis measured
as the degree of Ph-positivity in the CD341CD382 stem cell by
fluorescent in situ hybridization (FISH) is correlated with prog-
nosis and response to nilotinib,5 dasatinib,6 and imatinib first-line
therapy.7
Telomeres shorten with each cell division, and telomere length
(TL) reflects the replicative history of a cell. Previous studies in
peripheral blood (PB) cells of CML patients showed dramatically
reduced TL of leukemic cells as opposed to nonleukemic T cells8
and revealed a correlation of age-adapted TL with disease
stage, response to treatment, and remaining duration of CP8-13
(reviewed by Brümmendorf and Balabanov14). Apart from variation
related to the methodology used for TL measurement, telomere
biology in healthy individuals in vivo is substantially influenced by 2
main parameters, age and genetic interindividual variability.15
Although age adjustment of TL can now be easily achieved by
adaptation of individual results to healthy control cohorts, the high
and mostly genetic interindividual variability in TL15 has so far still
somewhat limited the prognostic and predictive value of routine TL
assessment in individual CML patients, as no patient-specific
BCR-ABL–negative internal control cells have been readily
available.
Here, we first investigated if telomere shortening can be detected
in LSC as opposed to nonclonal HSC, and, if so, the degree of
intraindividual telomere shortening in LSC at diagnosis was
correlated with leukemic involvement of the HSC compartment
and could thus potentially serve as a discriminator between early
and late CP CML. For this purpose, we analyzed TL in the
LSC and nonleukemic CD341CD382 HSC (DTLLSC-HSC) of
CP-CML patients at diagnosis using a modified confocal
quantitative FISH (Q-FISH) technique. Indeed, we were able to
establish a correlation between accelerated telomere shorten-
ing in LSC and the degree of leukemic involvement of the
CD341CD382 HSC compartment that (pending prospective
validation in clinical trials) could potentially become the first
epigenetic biomarker in newly diagnosed CML.
Given the rather limited accessibility of LSC and nonclonal HSC for
clinical routine prognostication of CML, we alternatively considered
to compare the previously established TL measurement in leukemic
myeloid PB cells obtained from CML patients at diagnosis8,13
to their nonclonal myeloid counterparts later obtained in deep
molecular remission. In order to validate this control population,
we first had to rule out a potential preexisting telomere deficit
in nonleukemic cells already present at the time of malignant
transformation (as it had been recently observed in AML patients).16
Furthermore, given the fact that long-lasting tyrosine kinase inhibitor
(TKI) treatment is typically required to achieve stable deep
molecular remission in CML patients before treatment discontinu-
ation, an effect of this treatment on TL in nonclonal myeloid cells had
to be included. These questions were prospectively addressed by
analyzing TL in PB of patients in deep molecular remission
eligible for treatment discontinuation as part of a German-Dutch
scientific substudy within the pan-European EURO-SKI trial
(NCT01596114).
Methods and patients
TL analysis of the BM slides
Single-blinded bone marrow (BM) samples were obtained from 15
patients of the first-line CML study (NCT00852566) of the Nordic
CML Study Group (NCMLSG).6 Inclusion criteria for the NCMLSG
trial were CML at first diagnosis in CP and no previous TKI
treatment (see Hjorth-Hansen et al6 and Mustjoki et al7). Detailed
patient characteristics are shown in Table 1. Written informed
consent was obtained from all patients, and the study was
conducted in accordance with the Declaration of Helsinki. Approval
by the ethical committee was given for all analyses. Initial cell
preparation was carried out as previously reported.7 Briefly, BM
samples from initial diagnosis were subjected to Ficoll separation;
next, CD341 cells were obtained by immune-magnetic bead
separation and subsequently stained with CD34 and CD38
antibodies. Next, CD341 cells were sorted by fluorescence-
activated cell sorting (80% being CD341CD381; 5% being
CD341CD382) and spun onto cytoslides. The percentage of
BCR-ABL1 and BCR-ABL2 cells was first determined by FISH,
using dual-fusion dual-color BCR-ABL1 probe (Vysis; Abbott
Laboratories, Abbott Park, IL), and clone size was calculated
according to standard procedures.7
In the next step, BCR-ABL FISH images of the sorted cell
populations (Figure 1A-B) were captured using a laser scanning
confocal microscope (LSCM; LSM710; Zeiss, Oberkochen,
Germany) running Zen 2009 software (Zeiss). Standard software
tools were used to save designated space coordinates (eg, x1, y1,
z1) for every image of the conditions. Image magnification was363.
Digital zoom was 32.5. Fifty to 100 cells per condition were
captured. The same cytoslides were then washed and reprocessed
for telomere Q-FISH (Figure 1B) using our previously published
protocol.17-20 Slides were dehydrated and air dried before telo-
meres were hybridized with a fluorescent Cy3-(C3TA2)-PNA probe
(Daejeon, Panagene, South Korea) for 2 hours. Slides were washed
in formamide buffer for 30 minutes before cell nuclei were
counterstained with 49,6-diamidino-2-phenylindole solution (Sigma,
Darmstadt, Germany). Cell relocalization at the LSCM was done
using an indirect approach based on a system of precoordinates
that allowed for a more precise tracking of the saved spots
previously captured. Multitracking mode of 0.5-mm steps was then
used to acquire the 49,6-diamidino-2-phenylindole and telomere
signal. Maximum intensity projections of 3 to 5 single consecutive
steps were carried out. To quantify the fluorescence intensity of the
telomere signal, images were analyzed using Definiens software
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(Definiens, Munich, Germany). Quantification of BCR-ABL FISH
staining and telomere Q-FISH analysis were carried out separately
in a single blinded fashion. Intensity of telomeres was given in
arbitrary units. Mean TL of BCR-ABL2 cells was subtracted from
BCR-ABL1 cells for each patient and calculated as DTLLSC-HSC in
order to minimize intraindividual TL variation.
Table 1. Clinical baseline data of the 15 patients enrolled in the Nordic first-line CML study (NCT00852566)
Patient number Age, y Sex Sokal score Euro score Clone size, % Leukocytes, 3 109/L Hb, g/dL Platelets, 3 109/L
1 72 M 0.93 1106 89 37 123 275
2 63 M 1.60 1902 91 119 99 264
3 51 F 0.82 1242 87 40 118 847
4 55 M 0.75 749 99 65.1 141 462
5 61 M 0.74 871 57 19.6 126 362
6 60 F 0.8 1002 75 97 111 401
7 61 M 1.39 1567 87 288 82 395
8 46 F 0.75 287 35 38.6 114 425
9 64 M 0.84 928 16 22 125 390
10 n.a. n.a. n.a. n.a. 30 n.a. n.a. n.a.
11 55 F 0.73 1053 79 75 95 137
12 61 F 0.90 1242 32 32 129 796
13 58 F 0.69 791 37 38 138 188
14 51 F 0.76 1177 48 73.9 129 503
15 41 F 0.67 204 83 11.4 137 706
F, female; Hb, hemoglobin; M, male; n.a., not available.
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Figure 1. Representative laser scanning confocal microscopy images obtained after applying a 2-phase combined FISH technique based on coordinate
assembly protocol for assessment of TL within the same CP CML patient’s CD341382 compartment. (A) In phase 1, BCR-ABL1 and BCR-ABL2 cells were
identified by BCR-ABL FISH staining. (B) In phase 2, PNA-Tel Q-FISH is used to restain the samples allowing telomere quantification in the BCR-ABL1 and BCR-ABL2 cells
within the same individual’s CD341382 compartment. Image magnification 3630. Digital zoom 32.5. DAPI, 49,6-diamidino-2-phenylindole.
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TL analysis of the PB
PB samples for TL analysis of 134 CML patients were prospec-
tively obtained within a scientific substudy of the pan-European
EURO-SKI trial (NCT01596114). Inclusion criteria of the EURO-SKI
trial were treatment by the TKI imatinib, dasatinib, or nilotinib for at
least 3 years and confirmed deep molecular response (MR4) (see
Saussele et al21). The primary aim of the study was to evaluate the
molecular relapse-free survival after TKI cessation. Written consent
was obtained from all patients, and the study was conducted in
accordance with the Declaration of Helsinki. Samples were ac-
quired at study inclusion, and TL analysis was carried out using flow
cytometry and FISH (flow-FISH) as described previously.18,19 Age
adaption was carried out on the basis of 356 healthy controls as
described previously, and TL is given in kilobases.18,19 Detailed
patient characteristics are shown in supplemental Table 1.
Statistical analysis
SPSS (version 16) was used for statistical analysis. Wilcoxon
matched pairs test, Pearson`s correlation, and 1-sample Student t
test were used for sample analysis. Log-rank test was used for
analysis of time toMR loss. Statistical significance was set at P, .05.
Results
TL in CD341382 LSC as a marker to discriminate early
from late CP CML
The purpose of the study was to test whether BCR-ABL–negative
HSC can be used as an internal intraindividual control for genetic
variability of TL in LSC. The aim was to gain deeper insights into the
clonal expansion of the LSC compartment during CP CML as a
potential reflection of whether an individual patient at diagnosis is
biologically still in early vs already in late CP.8 For this purpose, we
analyzed TL in individual BCR-ABL1 CD341CD382 sorted BM
cells of CML patients at first diagnosis and compared with their
phenotypically identical nonleukemic BCR-ABL2 CD341CD382
counterparts.7,22-24 Sequential LSCM for BCR-ABL FISH and
telomere Q-FISH was used (Figure 1A-B). In analogy to previous
studies in PB,8,13 we found a statistically significant telomere deficit
(24.9 arbitrary fluorescent units [a.u.] range: 253.7 to 16.9 a.u.,
P 5 .04) in BCR-ABL1 LSC compared with BCR-ABL2 non-
leukemic HSC at diagnosis (Figure 2A).
We next assessed whether size of the leukemic clone in CML patients
at diagnosis was indeed paralleled by accelerated telomere shortening
in the respective LSC fraction. The mean clone size (ie, proportion of
BCR-ABL1) in the CD341CD382 fraction of the study cohort of
BCR-ABL1 patients was 59.9%6 32% (mean6 standard deviation;
Table 1).We then calculated the difference in TL between BCR-ABL1
and BCR-ABL2 cells (DTLLSC-HSC) and correlated the difference with
the clone size. CML LSC burden was found to be directly
correlated with accelerated telomere shortening (expressed as
DTLLSC-HSC) probably due to the substantial replicative expan-
sion of the BCR-ABL1 stem cell pool already before diagnosis of
CML (R2 5 0.367; P 5 .016; n 5 15; Figure 2B).
TL in nonclonal cells assessed in deep
molecular remission
Based on previous results describing a preexisting TL deficit in
nonleukemic cells from patients with AML in remission after induction
therapy,16 we wanted to analyze TL in nonleukemic cells from CML
patients in MR.4 In addition, we aimed to investigate whether we
could detect a correlation between TL and previous TKI treatment
duration and/or a potential use of TL in nonclonal cells as a predictive
marker for molecular relapse after TKI cessation. Therefore, we
prospectively analyzed 134 CML patients enrolled into the telomere
substudy of the EURO-SKI trial. In order to correct for the well-
described age dependency of TL,15 we age-adapted TL of
granulocytes (aaTLgran) and lymphocytes (aaTLlymph) on the basis
of a preexisting large control cohort described previously.18,19
We observed that in lymphocytes mean aaTLlymph (20.22 6 1.6 kb,
n 5 133; P 5 .02) of CML patients was slightly but significantly
shortened (Figure 3A-C). In granulocytes, however, we did not detect a
statistically significant difference (0.16 6 1.13 kb, n 5 133; P 5 .10)
compared with age-adapted healthy donors (Figure 3B-C).
We next tested whether TL at time of TKI cessation correlates with
the risk of molecular relapse expressed as duration of molecular
remission after TKI cessation. Interestingly, we found a trend toward
a correlation between age-adjusted TL shortening and loss of major
molecular response (MR3) over time for the granulocyte (P 5 .08;
supplemental Figure 1A) but not for the lymphocyte (P 5 .12;
supplemental Figure 1B) compartment. We further wanted to
analyze the possible impact of previous duration of TKI treatment
before TKI cessation on TL in deep molecular remission. We did
not observe any significant correlation of aaTLlymph neither in the
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Figure 2. TL in BCR-ABL2 vs BCR-ABL1 cells of CP CML patients at first
diagnosis. (A) TL (in a.u.) in CD341CD382 BCR-ABL1 LSC is significantly
shortened compared with BCR-ABL2 HSC (P 5 .040). (B) Difference in TL between
BCR-ABL1 LSC and BCR-ABL2 HSC (DTLLSC-HSC, in a.u.) as a function of clone
size (ie, the percentage of Ph1 cells) in the BM CD341CD382 population of CP CML
patients at diagnosis (r2 5 0.367, P 5 .016).
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subgroup with loss of MR3 (R25 0.02, P5 .35) nor in the subgroup
with sustained MR3 (R2 5 0.03, P 5 .18; supplemental Figure 2A)
in the lymphocyte nor in the granulocyte subpopulation (R2 5 0.04,
P5 .13 for loss of MR3 and R2 5 0.01, P5 .46 for sustained MR3,
respectively) (supplemental Figure 2B).
Taken together and in line with previous pilot studies,10 TL in
nonleukemic granulocytes obtained in major molecular response
did not differ from healthy individuals. We conclude that durable
treatment (median duration of TKI treatment: 7.2 years, range 3.0 to
14.0 years) with TKIs did not seem to affect TL in nonleukemic
myelopoiesis. Whether TKI treatment might play a role for the rather
slight but significant shortening of TL observed in lymphocytes will
need to be investigated in follow-up studies.
Discussion
Despite its model character for molecular targeted therapy of
cancer,25 risk stratification and prognostication of CML have not
changed very much since the first development of the Sokal26 and
later Hasford Score27 in 1984 and 1998, respectively. Although
clinical scores became clinically more refined and adapted to the
TKI era, the modification and improvement toward the EUTOS28 or
ELTS29 score were mostly achieved by regrouping or different
weighing of clinical routine parameters. However, surprisingly and
different from most other hematological malignancies, only few
additional molecular or cytogenetic abnormalities have so far been
identified to gain clinical impact on prognostication or prediction of
treatment response in CML at diagnosis.30 This results in our
sustained inability to clinically predict phase transition from CP to
AP/BC, a clinical endpoint still of utmost importance because outside
allogeneic stem cell transplantation, prognosis in advanced stageCML
is still very poor with overall survival in the range of 6 to 12 months.
We have previously shown that TL measured in PB of patients with
CML can discriminate leukemic myeloid from nonleukemic T cells and
correlates with disease stage, clinical prognostic scores,11 and
response to treatment13,31 (reviewed in Keller et al32). In addition, we
could discriminate early vs late CP by correlating TL with remaining
duration of CP in retrospective analysis.8 Furthermore, TL was found
to correlate with Ph-positivity of long-term culture initiating cells,
LTC-IC measured by conventional cytogenetics (Tim H. Brümmendorf,
T. L. Holyoake, P. M. Lansdorp, C. Eaves, unpublished results).
Moreover, accelerated telomere shortening (typically observed in late
CP CML) in myeloid neoplasia was found to be associated with
genetic instability (reviewed in Ohyashiki et al33 and Vajen et al34) as
well as with a characteristic inflammatory signature (termed telomere-
associated secretory phenotype) potentially contributing to disease
progression in a murine model of BCR-ABL1, telomerase knock-out
cells.35 Finally, effective execution of telomerase inhibition in a CML
cell-line model was shown to be dependent of intact p53 signaling.36
Taken together, impaired telomere maintenance in leukemic as
opposed to non-LSCs is suggested to mirror disease progression
within CML CP and to be functionally involved in phase transition
toward AP/BC.
Until 20 years ago, prognostication of CML and other hematological
disorders (reviewed by Brümmendorf and Balabanov14) on the basis
of TL measurement has significantly been impaired by suboptimal
methodology, age dependency of the parameter, and even more so,
by substantial interindividual variability that (on the basis of twin
studies) can mostly be attributed to genetic causes.15 Substantial
improvements in the methodology to study TL in eukaryotes have
been introduced with the development of Q-FISH–based method-
ologies, particularly with flow-FISH to measure the average length of
telomeres in cells37 (also allowing to study large control cohorts used
for age-adaptation15,18,19,38). Nevertheless, genetic individual vari-
ability can only significantly be reduced by expressing TL in leukemic
(target) cells in relation to nonleukemic (control) cells with pre-
sumably normal TL. We therefore decided to analyze intraindividual
TL specifically in LSC in relation to HSC of selected patients with
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Figure 3. TL of 134 CML patients within the EURO-SKI
study. (A) TL (in kb) vs age (in years) in PB lymphocytes of
CML patients with loss of (orange squares; n 5 58) or
maintained (blue circles; n 5 75) molecular residual disease.
(B) TL (in kb) vs age (in years) in PB granulocytes of CML
patients with loss of (green squares; n 5 58) or maintained
(yellow circles; n 5 75) molecular residual disease. (C) Age-
adjusted TL (aaTL) of PB lymphocytes (shown in blue;
P 5 .020) and granulocytes (shown in yellow; P 5 .100) from
the EURO-SKI study patients. n.s., not significant.
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CML and to compare these results with the degree of Ph-positivity
in the CD341382 stem cell compartment at diagnosis. For this
purpose, we use a 2-step combination of routine FISH methodology
used for the identification of BCR-ABL1 cells5,7 with a recently
developed confocal Q-FISH for TL measurement.17 Thereby, we
could demonstrate for the first time that immature LSCs indeed have
significantly shortened TL compared with phenotypically identical
nonleukemic HSC at diagnosis, thus validating conclusions drawn
from previous TL measurements of PB cells and extending these
results to the HSC compartment.8,11,13,31 Interestingly and despite
the relatively small sample size available for analysis, accelerated
telomere shortening was found to be correlated with an increasing
leukemic clone size in the HSC compartment, a novel parameter that
was previously shown to be correlated with prognosis and response
to TKI treatment.5,7 It is important to note that other factors than the
replicative history of LSC alone are being reflected in the clone size
measured at diagnosis. However, together with previous studies,8,13 the
current data support the hypothesis that progressive telomere
shortening represents an epigenetic biomarker of CML LSC, correlates
with disease progression in CP, and (via increased genetic instability)39
contributes to phase transition of CML.
The assumption that nonleukemic myeloid cells in patients with
CML at diagnosis have unaltered TL (and could thereby be used
as controls) has not been formally proven to date. In theory and
in analogy to AML,16 nonleukemic cells could conceivably have
harbored a preexisting, preleukemic telomere deficit potentially
contributing to disease onset and evolution. Furthermore, CML cells
could potentially alter normal HSC via extrinsic factors that might
impact not only on their differentiation and self-renewal capacity but
eventually also on TL.40 Consequently, we decided to study TL in
nonleukemic cells of CML patients by analyzing the PB obtained in
deep molecular remission under TKI treatment within the EURO-SKI
study. We found that TL in nonleukemic cells from CML patients
was not different between myeloid and lymphoid cells (Figure 2C)
and, as opposed to previous studies in AML,16 not meaningfully
shortened in myeloid cells compared with age-adjusted controls.
Furthermore, no correlation between TKI treatment duration and
telomere shortening was observed arguing against sustained
replicative telomere-mediated damage to the nonleukemic HSC
pool as a consequence of long-lasting TKI treatment. The rather
discrete but significant shortening of TL in the lymphoid compart-
ment (that can be translated into 2 to 3 additional population
doublings) could potentially be attributed to an increased replicative
demand in the lymphoid compartment under TKI treatment and/or a
shift in lymphocyte subfractions (with known differences in
TL38,41,42) observed to a different degree under the individual TKI
treatments.
In conclusion, we propose that despite the presence of quiescent
HSC subfractions, overall BCR-ABL1 LSC are characterized by
an increased cellular turnover leading to accelerated telomere
shortening. At CML-CP diagnosis, telomeres in BCR-ABL1myeloid
cells and as shown here, also in CD341382 LSC, are already
significantly shortened compared with their respective nonleukemic
HSC counterparts, and this difference is increasing progressively
with decreasing remaining duration of CP.8 Potentially, replication-
independent mechanisms such as increased oxidative stress
due to BCR-ABL–mediated increased reactive oxygen species
production43 on the 1 hand and telomerase activity and/or alternative
lengthening of telomeres44 on the other hand might additionally
impact on TL (reviewed by Lansdorp45 and by Vasko et al46).
However, based on the overall continuous telomere shortening
observed, we hypothesized that, by measuring the degree of
effective telomere shortening in each individual patient, we might be
able to overcome the problem of interindividual variability in TL
assessment, thus allowing a better prediction of the remaining
duration of CP, and as a consequence, progression toward AP/BC
in the future.
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39. Samassekou O, Ntwari A, Hébert J, Yan J. Individual telomere lengths in chronic myeloid leukemia. Neoplasia. 2009;11(11):1146-1154.
40. Welner RS, Amabile G, Bararia D, et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor
cells. Cancer Cell. 2015;27(5):671-681.
41. Baerlocher GM, Lansdorp PM. Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry A. 2003;55(1):1-6.
42. Beier F, Balabanov S, Amberger CC, et al. Telomere length analysis in monocytes and lymphocytes from patients with systemic lupus erythematosus
using multi-color flow-FISH. Lupus. 2007;16(12):955-962.
43. Nieborowska-Skorska M, Kopinski PK, Ray R, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and
primitive progenitors. Blood. 2012;119(18):4253-4263.
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